AbudayyehOO, GootenbergJS, KonermannS, et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016; 353:aaf5573. DOI: 10.1126/science.aaf5573.
2.
AbudayyehOO, GootenbergJS, EssletzbichlerP, et al.RNA targeting with CRISPR–Cas13. Nature. 2017; 550:280–284. DOI: 10.1038/nature24049.
3.
GootenbergJS, AbudayyehOO, LeeJW, et al.Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017; 356:438–442. DOI: 10.1126/science.aam9321.
4.
FreijeCA, MyhrvoldC, BoehmCK, et al.Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell. 2019; 76:826–837.e11. DOI: 10.1016/j.molcel.2019.09.013.
5.
AckermanCM, MyhrvoldC, ThakkuSG, et al.Massively multiplexed nucleic acid detection with Cas13. Nature. 2020; 582:277–282. DOI: 10.1038/s41586-020-2279-8.
6.
MetskyHC, WelchNL, PillaiPP, et al.Designing sensitive viral diagnostics with machine learning. Nat Biotechnol. 2022; 1–9. DOI: 10.1038/s41587-022-01213-5.
7.
Arizti-SanzJ, FreijeCA, StantonAC, et al.Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun. 2020; 11:5921. DOI: 10.1038/s41467-020-19097-x.
8.
AbbottTR, DhamdhereG, LiuY, et al.Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020; 181:865–876.e12. DOI: 10.1016/j.cell.2020.04.020.
9.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021; 385:493–502. DOI: 10.1056/NEJMoa2107454.
10.
CharlesworthCT, DeshpandePS, DeverDP, et al.Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019; 25:249–254. DOI: 10.1038/s41591-018-0326-x.
11.
BaddeleyHJE, IsalanM. The application of CRISPR/Cas systems for antiviral therapy. Front Genome Ed. 2021; 3:745559. DOI: 10.3389/fgeed.2021.745559.
12.
XuC, ZhouY, XiaoQ, et al.Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes. Nat Methods. 2021; 18:499–506. DOI: 10.1038/s41592-021-01124-4.
